Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma

SIMPLE SUMMARY: Most melanoma patients have non-overlapping “driver” mutations in either BRAF, NRAS, or NF1 genes based on Next-Gen sequencing. Other overlapping genetic changes, termed “passenger mutations” may also be identified. The impact of these mutations on cancer immunotherapy outcome is cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Panning, Alyssa, Samlowski, Wolfram, Allred, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340344/
https://www.ncbi.nlm.nih.gov/pubmed/37444637
http://dx.doi.org/10.3390/cancers15133527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340344/
https://www.ncbi.nlm.nih.gov/pubmed/37444637
http://dx.doi.org/10.3390/cancers15133527

Ejemplares similares